GlaxoSmithKline's melanoma combo beats Roche's Zelboraf in Phase III

GlaxoSmithKline ($GSK) is touting stellar Phase III results for an in-development combo therapy for melanoma, saying its treatment beat out Roche's ($RHHBY) Zelboraf in overall survival and led independent advisers to recommend an early end for the study. GSK is testing a combination of the MEK inhibitor trametinib (approved as Mekinist) and the BRAF-blocking dabrafenib (Tafinlar) against Roche's drug in patients with cutaneous melanoma and mutations in their BRAF genes. In an interim analysis, the combo's overall survival benefit compared to Zelboraf crossed the prespecified stopping point, GSK said, and its independent data monitoring committee has recommended that the trial end early. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.